These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28333573)

  • 1. New approaches for characterization of the genetic stability of vaccine cell lines.
    Ng S; Gisonni-Lex L; Azizi A
    Hum Vaccin Immunother; 2017 Jul; 13(7):1669-1672. PubMed ID: 28333573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese vaccine products go global: vaccine development and quality control.
    Xu M; Liang Z; Xu Y; Wang J
    Expert Rev Vaccines; 2015 May; 14(5):763-73. PubMed ID: 25697690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic stability of vaccine strains by multilocus sequence typing and pulsed-field gel electrophoresis analysis: Implications for quality control of the leptospiral vaccine.
    Xu Y; Zhang J; Cui S; Li M; Zhang Y; Xue H; Xin X; Wang J
    Hum Vaccin Immunother; 2015; 11(5):1272-6. PubMed ID: 25806658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on current downstream bio-processing technology of vaccine products.
    Li M; Qiu YX
    Vaccine; 2013 Feb; 31(9):1264-7. PubMed ID: 23313813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of HSV-1 UL5 and UL29 gene copy numbers in an HSV complementing Vero cell line.
    Azizi A; Aidoo F; Gisonni-Lex L; McNeil B
    J Biotechnol; 2013 Dec; 168(4):382-7. PubMed ID: 24140636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High definition viral vaccine strain identity and stability testing using full-genome population data--The next generation of vaccine quality control.
    Höper D; Freuling CM; Müller T; Hanke D; von Messling V; Duchow K; Beer M; Mettenleiter TC
    Vaccine; 2015 Oct; 33(43):5829-5837. PubMed ID: 26387431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Need for new technologies for detection of adventitious agents in vaccines and other biological products.
    Mallet L; Gisonni-Lex L
    PDA J Pharm Sci Technol; 2014; 68(6):556-62. PubMed ID: 25475629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovations in vaccine development: can regulatory authorities keep up?
    Cox MM; Onraedt A
    Expert Rev Vaccines; 2012 Oct; 11(10):1171-3. PubMed ID: 23176649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of QbD for the development of a vaccine candidate.
    Haas J; Franklin A; Houser M; Maraldo D; Mikola M; Ortiz R; Sullivan E; Otero JM
    Vaccine; 2014 May; 32(24):2927-30. PubMed ID: 24598725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine stabilization: research, commercialization, and potential impact.
    Kristensen D; Chen D; Cummings R
    Vaccine; 2011 Sep; 29(41):7122-4. PubMed ID: 21651941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome.
    Onions D; Côté C; Love B; Toms B; Koduri S; Armstrong A; Chang A; Kolman J
    Vaccine; 2011 Sep; 29(41):7117-21. PubMed ID: 21651935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
    Huang CY; Kinney RM; Livengood JA; Bolling B; Arguello JJ; Luy BE; Silengo SJ; Boroughs KL; Stovall JL; Kalanidhi AP; Brault AC; Osorio JE; Stinchcomb DT
    PLoS Negl Trop Dis; 2013; 7(5):e2243. PubMed ID: 23738026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene.
    Reschner A; Scohy S; Vandermeulen G; Daukandt M; Jacques C; Michel B; Nauwynck H; Xhonneux F; Préat V; Vanderplasschen A; Szpirer C
    Hum Vaccin Immunother; 2013 Oct; 9(10):2203-10. PubMed ID: 24051431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.
    Shcherbik S; Sergent SB; Davis WG; Shu B; Barnes J; Kiseleva I; Larionova N; Klimov A; Bousse T
    J Virol Methods; 2014 Jan; 195():18-25. PubMed ID: 24056261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and characterization of novel fowlpox virus shuttle vectors.
    Du S; Liu C; Zhu Y; Wang Y; Ren D; Wang M; Tan P; Li X; Tian M; Zhang Y; Li J; Zhao F; Li C; Jin N
    Virus Res; 2015 Feb; 197():59-66. PubMed ID: 25529440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chain.
    Stewart M; Ward SJ; Drew J
    Vaccine; 2014 May; 32(24):2931-8. PubMed ID: 24662703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.
    Legastelois I; Buffin S; Peubez I; Mignon C; Sodoyer R; Werle B
    Hum Vaccin Immunother; 2017 Apr; 13(4):947-961. PubMed ID: 27905833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of passages during Japanese BCG vaccine production on genetic stability and protective efficacy.
    Seki M; Udagawa T; Sugawara I; Iwama K; Honda I; Fujita I; Hashimoto A; Yano I; Yamamoto S
    Vaccine; 2012 Feb; 30(8):1460-4. PubMed ID: 22226863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.